Syros Pharmaceuticals, Inc. - common stock (SYRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
SYRS POWR Grades
- Sentiment is the dimension where SYRS ranks best; there it ranks ahead of 90.4% of US stocks.
- The strongest trend for SYRS is in Sentiment, which has been heading up over the past 177 days.
- SYRS's current lowest rank is in the Momentum metric (where it is better than 10.29% of US stocks).
SYRS Stock Summary
- Of note is the ratio of SYROS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 7.62% of US stocks have a lower such ratio.
- In terms of volatility of its share price, SYRS is more volatile than 97.29% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SYRS comes in at -128.07% -- higher than that of just 4.3% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to SYROS PHARMACEUTICALS INC, a group of peers worth examining would be CLLS, GSIT, CTMX, EIGR, and PIRS.
- Visit SYRS's SEC page to see the company's official filings. To visit the company's web site, go to www.syros.com.
SYRS Valuation Summary
- In comparison to the median Healthcare stock, SYRS's price/earnings ratio is 104.07% lower, now standing at -0.9.
- Over the past 80 months, SYRS's price/earnings ratio has gone up 9.1.
Below are key valuation metrics over time for SYRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SYRS | 2023-01-30 | 4.2 | 0.8 | -0.9 | 0.1 |
| SYRS | 2023-01-27 | 3.9 | 0.7 | -0.8 | 0.2 |
| SYRS | 2023-01-26 | 3.8 | 0.7 | -0.8 | 0.2 |
| SYRS | 2023-01-25 | 3.8 | 0.7 | -0.8 | 0.2 |
| SYRS | 2023-01-24 | 3.8 | 0.7 | -0.8 | 0.2 |
| SYRS | 2023-01-23 | 3.9 | 0.7 | -0.8 | 0.2 |
SYRS Growth Metrics
- The 4 year revenue growth rate now stands at 175.53%.
- Its 3 year net cashflow from operations growth rate is now at -84.69%.
- Its 4 year net cashflow from operations growth rate is now at 7.16%.
The table below shows SYRS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 23.436 | -114.951 | -113.693 |
| 2022-06-30 | 25.242 | -107.291 | -109.467 |
| 2022-03-31 | 24.128 | -107.567 | -97.476 |
| 2021-12-31 | 23.488 | -99.54 | -86.558 |
| 2021-09-30 | 21.385 | -106.495 | -92.875 |
| 2021-06-30 | 19.516 | -93.623 | -86.334 |
SYRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SYRS has a Quality Grade of C, ranking ahead of 31.76% of graded US stocks.
- SYRS's asset turnover comes in at 0.093 -- ranking 271st of 682 Pharmaceutical Products stocks.
- ONVO, OPK, and ICPT are the stocks whose asset turnover ratios are most correlated with SYRS.
The table below shows SYRS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.093 | 1 | -1.040 |
| 2021-03-31 | 0.093 | 1 | -1.148 |
| 2020-12-31 | 0.092 | 1 | -1.221 |
| 2020-09-30 | 0.067 | 1 | -0.971 |
| 2020-06-30 | 0.044 | 1 | -0.838 |
| 2020-03-31 | 0.026 | 1 | -0.889 |
SYRS Price Target
For more insight on analysts targets of SYRS, see our SYRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.29 | Average Broker Recommendation | 1.44 (Moderate Buy) |
SYRS Stock Price Chart Interactive Chart >
SYRS Price/Volume Stats
| Current price | $4.93 | 52-week high | $18.10 |
| Prev. close | $5.05 | 52-week low | $3.02 |
| Day low | $4.83 | Volume | 123,200 |
| Day high | $5.20 | Avg. volume | 151,292 |
| 50-day MA | $3.98 | Dividend yield | N/A |
| 200-day MA | $6.73 | Market Cap | 99.71M |
Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.
Latest SYRS News From Around the Web
Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic SyndromeCAMBRIDGE, Mass., January 26, 2023--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is cur |
Syros Announces Clinical Updates and 2023 Strategic PrioritiesCAMBRIDGE, Mass., January 09, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023. |
Syros Pharmaceuticals''s Return On Capital Employed OverviewAccording to data from Benzinga Pro, during Q3, Syros Pharmaceuticals ''s (NASDAQ: SYRS ) reported sales totaled $3.89 million. Despite a 12.26% increase in earnings, the company posted a loss of $30.25 million. Syros Pharmaceuticals collected $6.28 million in revenue during Q2, but reported earnings showed a $34.48 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com |
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., December 23, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
SYRS Price Returns
| 1-mo | 38.48% |
| 3-mo | 39.66% |
| 6-mo | -46.99% |
| 1-year | -71.67% |
| 3-year | -93.07% |
| 5-year | -95.04% |
| YTD | 37.33% |
| 2022 | -88.99% |
| 2021 | -69.95% |
| 2020 | 57.02% |
| 2019 | 24.06% |
| 2018 | -42.75% |
Continue Researching SYRS
Want to see what other sources are saying about Syros Pharmaceuticals Inc's financials and stock price? Try the links below:Syros Pharmaceuticals Inc (SYRS) Stock Price | Nasdaq
Syros Pharmaceuticals Inc (SYRS) Stock Quote, History and News - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...